Gensight Biologics (France) Today
| SIGHT Stock | EUR 0.24 0.02 7.69% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Gensight Biologics is selling at 0.24 as of the 23rd of March 2025; that is 7.69% down since the beginning of the trading day. The stock's last reported lowest price was 0.23. Gensight Biologics has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. GenSight Biologics S.A. was founded in 2012 and is headquartered in Paris, France. The company has 46.16 M outstanding shares. More on Gensight Biologics SA
Moving together with Gensight Stock
Moving against Gensight Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Gensight Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Gensight Biologics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Gensight Biologics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Bernard Gilly |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Gensight Biologics SA (SIGHT) is traded on Euronext Paris in France and employs 44 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 144.58 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gensight Biologics's market, we take the total number of its shares issued and multiply it by Gensight Biologics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Gensight Biologics operates under Biotechnology sector and is part of Health Care industry. The entity has 46.16 M outstanding shares.
Gensight Biologics SA has accumulated about 44.29 M in cash with (17.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Gensight Biologics Probability Of Bankruptcy
Ownership AllocationGensight Biologics SA has a total of 46.16 Million outstanding shares. 30% of Gensight Biologics outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Gensight Ownership Details
Gensight Biologics Risk Profiles
Although Gensight Biologics' alpha and beta are two of the key measurements used to evaluate Gensight Biologics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.28 | |||
| Standard Deviation | 4.74 | |||
| Variance | 22.5 | |||
| Risk Adjusted Performance | (0.04) |
Gensight Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Gensight Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Gensight Biologics Corporate Management
Elected by the shareholders, the Gensight Biologics' board of directors comprises two types of representatives: Gensight Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gensight. The board's role is to monitor Gensight Biologics' management team and ensure that shareholders' interests are well served. Gensight Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gensight Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Serge Picaud | Scientific Board | Profile | |
| Scott Jeffers | Chief Officer | Profile | |
| Clothilde Caillet | Director Communication | Profile | |
| Pr Roska | Scientific Board | Profile | |
| Thomas Gidoin | Chief Officer | Profile | |
| JoseAlain MD | Vice Founder | Profile |
Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.